New Preoperative Regimen Gets a Win in Pancreatic Cancer

New Preoperative Regimen Gets a Win in Pancreatic Cancer

(MedPage Today) -- CHICAGO -- A neoadjuvant chemotherapy regimen of cisplatin (Platinol), nab-paclitaxel (Abraxane), capecitabine (Xeloda), and gemcitabine (PAXG) topped a standard option in a randomized trial of resectable or borderline resectable...

JCI Switching on the evolutionary potential of pancreatic cancer: the tumor suppressor functions of PBRM1

Cell plasticity is a hallmark of cancer, enabling tumor cells to acquire multiple phenotypes responsible for tumor progression, metastasis, and therapy resistance. In this issue of the JCI, Kawai and colleagues leveraged genetically engineered mouse models (GEMM) of pancreatic ductal adenocarcinoma (PDAC) to demonstrate that loss of Pbrm1, a member of the SWI/SNF complex, drives dedifferentiation and aggressive tumor features. Pbrm1 loss activat…

EU Shield Consortium Launches To Cut Pancreatic Cancer Mortality Rate - Data Intelligence

Pancreatic cancer is the fourth leading cancer in Europe. Image credit: SewCreamStudio via Shutterstock A new EU consortium has launched with the aim to reduce pancreatic cancer mortality rate across the continent. Project Shield, aiming to introduce comprehensive surveillance of high-risk individuals and use multiplex immunoassays to drive early detection of pancreatic cancer in routine cancer screening programmes, is comprised of 26 partners a…

EU Shield consortium launches to cut pancreatic cancer mortality rate

A new EU consortium has launched with the aim to reduce pancreatic cancer mortality rate across the continent.The post EU Shield consortium launches to cut pancreatic cancer mortality rate appeared first on Medical Device Network.